Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies

References

• Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology–drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157–1167.
   PubMed Web of Science ®Google Scholar
• Koren G. Therapeutic drug monitoring principles in the neonate. Clin Chem. 1997;43(1):222–227.
   PubMed Web of Science ®Google Scholar
• Wagner C, Zhao P, Pan Y, et al. Application of physiologically based pharmacokinetic (PBPK) modeling to support dose selection: report of an FDA public workshop on PBPK. CPT Pharmacometrics Syst Pharmacol. 2015;4(4):226–230.
   PubMedGoogle Scholar
• Maharaj AR, Edginton AN. Physiologically based pharmacokinetic modeling and simulation in pediatric drug development. CPT Pharmacometrics Syst Pharmacol. 2014;3(11):1–13.
   PubMedGoogle Scholar
• Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet. 2006;45(10):1013–1034.
   PubMed Web of Science ®Google Scholar
• Hornik CP, Wu H, Edginton AN, et al. Development of a pediatric physiologically based pharmacokinetic model of clindamycin using opportunistic pharmacokinetic data. Clin Pharmacokinet. 2017;56(11):1343–1353.
   PubMed Web of Science ®Google Scholar
• Emoto C, Fukuda T, Johnson TN, et al. Development of a pediatric physiologically based pharmacokinetic model for sirolimus: applying principles of growth and maturation in neonates and infants. CPT Pharmacometrics Syst Pharmacol. 2015;4(2):e17.
   PubMedGoogle Scholar
• Duan P, Fisher JW, Wang J. Applications of physiologically based pharmacokinetic (PBPK) models for pediatric populations. In: Mahmood I, Burckart G, editors. Fundamentals of pediatric drug dosing. Cham: Springer International Publishing; 2016. p. 109–125.
   Google Scholar
• Rioux N, Waters NJ. Physiologically based pharmacokinetic modeling in pediatric oncology drug development. Drug Metab Dispos. 2016;44(7):934–943.
   PubMed Web of Science ®Google Scholar
• Delaney SR, Malik PRV, Stefan C, et al. Predicting escitalopram exposure to breastfeeding infants: integrating analytical and in silico techniques. Clin Pharmacokinet. 2018 April 12. epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Edginton AN, Theil FP, Schmitt W, et al. Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol. 2008;4(9):1143–1152.
   PubMed Web of Science ®Google Scholar
• Edlund H, Melin J, Parra-Guillen ZP, et al. Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children. Clin Pharmacokinet. 2015;54(1):35–80.
   PubMed Web of Science ®Google Scholar
• Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548–558.
   PubMed Web of Science ®Google Scholar
• Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT: Pharmacometrics Syst Pharmacol. 2017;6(9):576–588.
   PubMedGoogle Scholar
• Garg A, Balthasar JP. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn. 2007;34(5):687–709.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wei X, Bajaj G, et al. Challenges and considerations for development of therapeutic proteins in pediatric patients. J Clin Pharmacol. 2015;55(Suppl 3):S103–S15.
   PubMed Web of Science ®Google Scholar
• Xu Z, Davis HM, Zhou H. Rational development and utilization of antibody-based therapeutic proteins in pediatrics. Pharmacol Ther. 2013;137(2):225–247.
   PubMed Web of Science ®Google Scholar
• Shi R, Derendorf H. Pediatric dosing and body size in biotherapeutics. Pharmaceutics. 2010;2(4):389.
   PubMedGoogle Scholar
• Yanni S. Disposition and interaction of biotherapeutics in pediatric populations. Curr Drug Metab. 2012;13(7):882–900.
   PubMed Web of Science ®Google Scholar
• Mahmood I. Pharmacokinetic considerations in designing pediatric studies of proteins, antibodies, and plasma-derived products. Am J Ther. 2016;23(4):e1043–e56.
   PubMed Web of Science ®Google Scholar
• Lerner G, Kale AS, Warady BA, et al. Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. Pediatr Nephrol. 2002;17(11):933–937.
   PubMed Web of Science ®Google Scholar
• Villar A, Aronis S, Morfini M, et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia. A. Haemophilia. 2004;10(4):352–359.
   PubMed Web of Science ®Google Scholar
• Blanchette VS, Shapiro AD, Liesner RJ, et al. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haeomst. 2008;6(8):1319–1326.
   PubMed Web of Science ®Google Scholar
• Monahan PE, Liesner R, Sullivan ST, et al. Safety and efficacy of investigator-prescribed BeneFIX prophylaxis in children less than 6 years of age with severe haemophilia B. Haemophilia. 2010;16(3):460–468.
   PubMed Web of Science ®Google Scholar
• Bjorkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia. 2001;7(2):133–139.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Gridelli BG, Martin S, et al. Basiliximab in pediatric liver transplantation: a pharmacokinetic-derived dosing algorithm. Pediatr Transplant. 2002;6(3):224–230.
   PubMed Web of Science ®Google Scholar
• Offner G, Broyer M, Niaudet P, et al. A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients. Transplantation. 2002;74(7):961–966.
   PubMed Web of Science ®Google Scholar
• Nagai T, Gotoh Y, Watarai Y, et al. Pharmacokinetics and pharmacodynamics of basiliximab in Japanese pediatric renal transplant patients. Int J Clin Pharmacol Ther. 2010;48(3):214–223.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Offner G, Broyer M, et al. A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations. Transplantation. 2002;74(7):966–971.
   PubMed Web of Science ®Google Scholar
• Han K, Peyret T, Quartino A, et al. Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation. Br J Clin Pharmacol. 2016;81(1):148–160.
   PubMed Web of Science ®Google Scholar
• Gojo J, Sauermann R, Knaack U, et al. Pharmacokinetics of bevacizumab in three patients under the age of 3 years with CNS malignancies. Drugs in R&D. 2017;17(3):469-474.
   PubMed Web of Science ®Google Scholar
• Glade Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol. 2008;26(3):399–405.
   PubMed Web of Science ®Google Scholar
• Trippett TM, Herzog C, Whitlock JA, et al. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators’ consortium. J Clin Oncol. 2009;27(30):5102–5108.
   PubMed Web of Science ®Google Scholar
• Pescovitz MD, Knechtle S, Alexander SR, et al. Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. Pediatr Transplant. 2008;12(4):447–455.
   PubMed Web of Science ®Google Scholar
• Desai AV, Fox E, Smith LM, et al. Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma. Cancer Chemother Pharmacol. 2014;74(5):1047–1055.
   PubMed Web of Science ®Google Scholar
• Gilman AL, Ozkaynak MF, Matthay KK, et al. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children’s Oncology Group. J Clin Oncol. 2009;27(1):85–91.
   PubMed Web of Science ®Google Scholar
• Greenbaum LA, Fila M, Ardissino G, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016;89(3):701–711.
   PubMed Web of Science ®Google Scholar
• Buckwalter M, Dowell JA, Korth-Bradley J, et al. Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Pharmacol. 2004;44(8):873–880.
   PubMed Web of Science ®Google Scholar
• Xu Z, Mould D, Hu C, et al. Population pharmacokinetic analysis of infliximab in pediatrics using integrated data from six clinical trials. Clin Pharmacol Drug Dev. 2012;4:203.
   Google Scholar
• Burns JC, Best BM, Mejias A, et al. Infliximab treatment of intravenous immunoglobulin–resistant Kawasaki disease. J Pediatr. 2008;153(6):833–838.e6.
   PubMed Web of Science ®Google Scholar
• Candon S, Mosca A, Ruemmele F, et al. Clinical and biological consequences of immunization to infliximab in pediatric Crohn’s disease. Clin Immunol. 2006;118(1):11–19.
   PubMed Web of Science ®Google Scholar
• Abarca K, Jung E, Fernandez P, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children. Pediatr Infect Dis J. 2009;28(4):267–272.
   PubMed Web of Science ®Google Scholar
• Fernández P, Trenholme A, Abarca K, et al. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season. BMC Pediatr. 2010;10(1):38.
   PubMedGoogle Scholar
• Lagos R, DeVincenzo JP, Muñoz A, et al. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children. Pediatr Infect Dis J. 2009;28(9):835–837.
   PubMed Web of Science ®Google Scholar
• Feltes TF, Sondheimer HM, Tulloh RMR, et al. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res. 2011;70:186.
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Chandran A, Weatherholtz R, et al. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. Lancet Infect Dis. 2015;15(12):1398–1408.
   PubMed Web of Science ®Google Scholar
• Weisman LE, Thackray HM, Steinhorn RH, et al. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Pediatrics. 2011;128(2):271–279.
   PubMed Web of Science ®Google Scholar
• Kokai-Kun JF, Mould D, Weisman LE, et al. Predicted and measured pagibaximab serum levels in high-risk neonates. Pediatr Res. 2010;68:683.
   Web of Science ®Google Scholar
• Subramanian KN, Weisman LE, Rhodes T, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J. 1998;17(2):110–115.
   PubMed Web of Science ®Google Scholar
• Saez-Llorens X, Moreno MT, Ramilo O, et al. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J. 2004;23(8):707–712.
   PubMed Web of Science ®Google Scholar
• Saez-Llorens X, Castano E, Null D, et al. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group. Pediatr Infect Dis J. 1998;17(9):787–791.
   PubMed Web of Science ®Google Scholar
• Robbie GJ, Makari D, Harris B, et al. Randomized, double-blind study of the pharmacokinetics and safety of palivizumab liquid formulation compared with lyophilized formulation. Infect Dis Ther. 2014;3(2):203–214.
   PubMedGoogle Scholar
• Pranzatelli MR, Tate ED, Verhulst SJ, et al. Pediatric dosing of rituximab revisited: serum concentrations in opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol. 2010;32(5):e167–72.
   PubMed Web of Science ®Google Scholar
• Meissner HC, Groothuis JR, Rodriguez WJ, et al. Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease. Antimicrob Agents Chemother. 1999;43(5):1183–1188.
   PubMed Web of Science ®Google Scholar
• Dostalek M, Gardner I, Gurbaxani BM, et al. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet. 2013;52(2):83–124.
   PubMed Web of Science ®Google Scholar
• Liu L. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell. 2018;9(1):15–32.
   PubMed Web of Science ®Google Scholar
• Malik P, Phipps C, Edginton A, et al. Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer. Pharm Res. 2017;34(12):2579–2595.
   PubMed Web of Science ®Google Scholar
• Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645–2668.
   PubMed Web of Science ®Google Scholar
• Tabrizi MA, Tseng C-ML, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11(1):81–88.
   PubMed Web of Science ®Google Scholar
• Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28(6):507–532.
   PubMed Web of Science ®Google Scholar
• Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res. 2010;2:14.
   PubMedGoogle Scholar
• Pyzik M, Rath T, Lencer WI, et al. FcRn: the architect behind the immune and non-immune functions of IgG and albumin. J Immunol. 2015;194(10):4595–4603.
   PubMed Web of Science ®Google Scholar
• Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2012;39(1):67–86.
   PubMed Web of Science ®Google Scholar
• Tzaban S, Massol RH, Yen E, et al. The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity. J Cell Biol. 2009;185(4):673–684.
   PubMed Web of Science ®Google Scholar
• Report of the Second Task Force on Blood Pressure Control in Children–1987. Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda, Maryland. Pediatrics. 1987;79(1):1–25.
   PubMed Web of Science ®Google Scholar
• Fleming S, Thompson M, Stevens R, et al. Normal ranges of heart rate and respiratory rate in children from birth to 18 years: a systematic review of observational studies. Lancet. 2011;377(9770):1011–1018.
   PubMed Web of Science ®Google Scholar
• Linderkamp O, Versmold HT, Riegel KP, et al. Estimation and prediction of blood volume in infants and children. Eur J Pediatr. 1977;125(4):227–234.
   PubMed Web of Science ®Google Scholar
• Jopling J, Henry E, Wiedmeier SE, et al. Reference ranges for hematocrit and blood hemoglobin concentration during the neonatal period: data from a multihospital health care system. Pediatrics. 2009;123(2):e333–7.
   PubMed Web of Science ®Google Scholar
• Friis-Hansen B. Body water compartments in children: changes during growth and related changes in body composition. Pediatrics. 1961;28(2):169–181.
   PubMed Web of Science ®Google Scholar
• Domachowske JB, Khan A, Esser MT, et al. A single dose monoclonal antibody (mAb) immunoprophylaxis strategy to prevent RSV disease in all infants: results of the first in infant study with MEDI8897. Open Forum Infect Dis. 2017;4(suppl_1):S37.
   Google Scholar
• Zhao L, Roskos L, Griffin P, et al. Population pharmacokinetics analysis of motavizumab in children at risk for respiratory syncytial virus infection. Pediatr Res. 2010;68(S1):447.
   Google Scholar
• Weisman LE, Thackray HM, Garcia-Prats JA, et al. Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates. Antimicrob Agents Chemother. 2009;53(7):2879–2886.
   PubMed Web of Science ®Google Scholar
• Robbie GJ, Zhao L, Mondick J, et al. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob Agents Chemother. 2012;56(9):4927–4936.
   PubMed Web of Science ®Google Scholar
• Lopez EL, Contrini MM, Glatstein E, et al. Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli. Antimicrob Agents Chemother. 2010;54(1):239–243.
   PubMed Web of Science ®Google Scholar
• Heymann MA, Iwamoto HS, Rudolph AM. Factors affecting changes in the neonatal systemic circulation. Annu Rev Physiol. 1981;43:371–383.
   PubMed Web of Science ®Google Scholar
• Mollison PL, Veall N, Cutbush M. Red cell and plasma volume in newborn infants. Arch Dis Child. 1950;25(123):242–253.
   PubMed Web of Science ®Google Scholar
• Steele MW. Plasma volume changes in the neonate. Am J Dis Child. 1962;103:10–18.
   PubMedGoogle Scholar
• Jegier W, Maclaurin J, Blankenship W, et al. Comparative study of blood volume estimation in the newborn infant using I-131 labeled human serum albumin (IHSA) and T-1824. Scand J Clin Lab Invest. 1964;16:125–132.
   PubMed Web of Science ®Google Scholar
• Cassady G. Plasma volume studies in low birth weight infants. Pediatrics. 1966;38(6):1020–1027.
   PubMedGoogle Scholar
• Parving HH, Klebe JG, Ingomar CJ. Simultaneous determination of plasma volume and transcapillary escape rate with 131 I-labelled albumin and T-1824 in the newborn. Acta Paediatr. 1973;62(3):248–252.
   Web of Science ®Google Scholar
• Ingomar CJ, Klebe JG, Baekgaard P. The transcapillary escape rate of T-1824 in healthy newborn infants–the influence of placental transfusion. Acta Paediatr. 1973;62(6):617–620.
   Web of Science ®Google Scholar
• Ingomar CJ, Klebe JG. The transcapillary escape rate of T-1824 in newborn infants of diabetic mothers and newborn infants with respiratory distress or birth asphyxia. Acta Paediatr. 1974;63(4):565–570.
   Web of Science ®Google Scholar
• Linderkamp O, Mader T, Butenandt O, et al. Plasma volume estimation in severely ill infants and children using a simplified Evans blue method. Eur J Pediatr. 1977;125(2):135–141.
   PubMed Web of Science ®Google Scholar
• Tassani P, Schad H, Schreiber C, et al. Extravasation of albumin after cardiopulmonary bypass in newborns. J Cardiothorac Vasc Anesth. 2007;21(2):174–178.
   PubMed Web of Science ®Google Scholar
• Parving HH, Gyntelberg F. Transcapillary escape rate of albumin and plasma volume in essential hypertension. Circ Res. 1973;32(5):643–652.
   PubMed Web of Science ®Google Scholar
• Rossing N, Parving HH, Lassen NA. Albumin transcapillary escape rate as an approach to microvascular physiology in health and disease. In: Bianchi R, Mariani G, McFarlane AS, editors. Plasma protein turnover. London: Palgrave Macmillan UK; 1976. p. 357–370.
   Google Scholar
• Wasserman K, Mayerson HS. Dynamics of lymph and plasma protein exchange. Cardiology. 1952;21(4–5):296–307.
   Google Scholar
• Malik PRV, Hamadeh A, Phipps C, et al. Population PBPK modelling of trastuzumab: a framework for quantifying and predicting inter-individual variability. J Pharmacokinet Pharmacodyn. 2017;44(3):277–290.
   PubMed Web of Science ®Google Scholar
• Nagy JA, Benjamin L, Zeng H, et al. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis. 2008;11(2):109–119.
   PubMed Web of Science ®Google Scholar
• Levick JR. Chapter 9 - Circulation of fluid between plasma, interstitium and lymph. An introduction to cardiovascular physiology. London, England: Butterworth-Heinemann; 1991. p. 142–170.
   Google Scholar
• Reed RK, Aukland K. Transcapillary fluid balance in immature rats–interstitial fluid pressure, serum and interstitial protein concentration, and colloid osmotic pressure. Microvasc Res. 1977;14(1):37–43.
   PubMed Web of Science ®Google Scholar
• Turner AJ, Brown RD, Carlström M, et al. Mechanisms of neonatal increase in glomerular filtration rate. Am J Physiol Regul Integr Comp Physiol. 2008;295(3):R916–R921.
   PubMed Web of Science ®Google Scholar
• Spitzer A, Edelmann CM Jr. Maturational changes in pressure gradients for glomerular filtration. Am J Physiol. 1971;221(5):1431–1435.
   PubMedGoogle Scholar
• Brace RA, Christian JL. Transcapillary Starling pressures in the fetus, newborn, adult, and pregnant adult. Am J Physiol Heart Circ Physiol. 1981;240(6):H843–H47.
   Google Scholar
• Spitzer A, Schwartz GJ. The kidney during development. Comprehensive physiology. John Wiley & Sons, Inc.; Supplement 25, 475-544, 2011.
   Google Scholar
• Rubin MI, Bruck E, Rapoport M, et al. Maturation of renal function in childhood: clearance studies. J Clin Invest. 1949;28(5 Pt 2):1144.
   Web of Science ®Google Scholar
• Oian P, Maltau JM. Calculated capillary hydrostatic pressure in normal pregnancy and preeclampsia. Am J Obstet Gynecol. 1987;157(1):102–106.
   PubMed Web of Science ®Google Scholar
• Sola A, Gregory GA. Colloid osmotic pressure of normal newborns and premature infants. Crit Care Med. 1981;9(8):568–572.
   PubMed Web of Science ®Google Scholar
• Delivoria-Papadopoulos M, Battaglia FC, Meschia G. A comparison of fetal versus maternal plasma colloidal osmotic pressure in man. Proc Soc Exp Biol Med. 1969;131(1):84–87.
   PubMedGoogle Scholar
• Sussmane JB, De Soto M, Torbati D. Plasma colloid osmotic pressure in healthy infants. Crit Care. 2001;5(5):261–264.
   PubMed Web of Science ®Google Scholar
• Wu PYK, Rockwell G, Chan L, et al. Colloid osmotic pressure in newborn infants: variations with birth weight, gestational age, total serum solids, and mean arterial pressure. Pediatrics. 1981;68(6):814–819.
   PubMed Web of Science ®Google Scholar
• Baum JD, Eisenberg C, Franklin JRFA, et al. Studies on colloid osmotic pressure in the fetus and newborn infant. Neonatology. 1971;18(3–4):311–320.
   Google Scholar
• Bhat R, Javed S, Malalis L, et al. Critical care problems in neonates–colloid osmotic pressure in healthy and sick neonates. Crit Care Med. 1981;9(8):563–567.
   PubMed Web of Science ®Google Scholar
• Hay DA, Evan AP. Maturation of the glomerular visceral epithelium and capillary endothelium in the puppy kidney. Anat Rec. 1979;193(1):1–21.
   PubMedGoogle Scholar
• Touwslager RN, Houben AJ, Tan FE, et al. Growth and endothelial function in the first 2 years of life. J Pediatr. 2015;166(3):666–71.e1.
   PubMed Web of Science ®Google Scholar
• Touwslager RN, Gerver WJ, Tan FE, et al. Influence of growth during infancy on endothelium-dependent vasodilatation at the age of 6 months. Hypertension. 2012;60(5):1294–1300.
   PubMed Web of Science ®Google Scholar
• Charpie JR, Schreur KD, Papadopoulos SM, et al. Endothelium dependency of contractile activity differs in infant and adult vertebral arteries. J Clin Invest. 1994;93(3):1339–1343.
   PubMed Web of Science ®Google Scholar
• Schaefer B, Bartosova M, Macher-Goeppinger S, et al. Quantitative histomorphometry of the healthy peritoneum. Sci Rep. 2016;6:21344.
   Google Scholar
• Celander O, Marild K. Regional circulation and capillary filtration in relation to capillary exchange in the foot and calf of the newborn infant. Acta Paediatr. 1962;51(3):385–400.
   PubMedGoogle Scholar
• Perera P, Kurban AK, Ryan TJ. The development of the cutaneous microvascular system in the newborn. Br J Dermatol. 1970;82:86–91.
   Google Scholar
• Top AP, Van Dijk M, Van Velzen JE, et al. Functional capillary density decreases after the first week of life in term neonates. Neonatology. 2011;99(1):73–77.
   PubMed Web of Science ®Google Scholar
• D’Souza R, Raghuraman RP, Nathan P, et al. Low birth weight infants do not have capillary rarefaction at birth: implications for early life influence on microcirculation. Hypertension. 2011;58(5):847–851.
   PubMed Web of Science ®Google Scholar
• Antonios TFT, Raghuraman RP, D’Souza R, et al. Capillary remodeling in infants born to hypertensive pregnancy: pilot study. Am J Hypertens. 2012;25(8):848–853.
   PubMed Web of Science ®Google Scholar
• Valentin J. Basic anatomical and physiological data for use in radiological protection: reference values. Ann ICRP. 2002;32(3):1–277.
   Google Scholar
• Tang L, Persky AM, Hochhaus G, et al. Pharmacokinetic aspects of biotechnology products. J Pharm Sci. 2004;93(9):2184–2204.
   PubMed Web of Science ®Google Scholar
• Correia IR. Stability of IgG isotypes in serum. mAbs. 2010;2(3):221–232.
   PubMed Web of Science ®Google Scholar
• Xu S. Internalization, trafficking, intracellular processing and actions of antibody-drug conjugates. Pharma Res. 2015;32(11):3577–3583.
   Google Scholar
• Deissler HL, Lang GK, Lang GE. Internalization of bevacizumab by retinal endothelial cells and its intracellular fate: evidence for an involvement of the neonatal Fc receptor. Exp Eye Res. 2016;143(SupplementC):49–59.
   PubMedGoogle Scholar
• Ritchie M, Tchistiakova L, Scott N. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. mAbs. 2013;5(1):13–21.
   PubMed Web of Science ®Google Scholar
• Shih LB, Lu HHZ, Xuan H, et al. Internalization and intracellular processing of an anti B-cell lymphoma monoclonal antibody, ll2. Int J Cancer. 1994;56(4):538–545.
   PubMed Web of Science ®Google Scholar
• Okeley NM, Miyamoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010;16(3):888–897.
   PubMed Web of Science ®Google Scholar
• Erickson HK, Park PU, Widdison WC, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006;66(8):4426–4433.
   PubMed Web of Science ®Google Scholar
• Gessner JE, Heiken H, Tamm A, et al. The IgG Fc receptor family. Ann Hematol. 1998;76(6):231–248.
   PubMed Web of Science ®Google Scholar
• Ferl GZ, Theil F-P, Wong H. Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini-review on fundamental concepts and applications. Biopharm Drug Dispos. 2016;37(2):75–92.
   PubMed Web of Science ®Google Scholar
• Glassman PM, Balthasar JP. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies. J Pharmacokinet Pharmacodyn. 2016;43(4):427–446.
   PubMed Web of Science ®Google Scholar
• Abuqayyas L, Zhang X, Balthasar JP. Application of knockout mouse models to investigate the influence of FcgammaR on the pharmacokinetics and anti-platelet effects of MWReg30, a monoclonal anti-GPIIb antibody. Int J Pharm. 2013;444(1–2):185–192.
   PubMedGoogle Scholar
• Abuqayyas L, Balthasar JP. Application of knockout mouse models to investigate the influence of FcgammaR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody. Int J Pharm. 2012;439(1–2):8–16.
   PubMedGoogle Scholar
• Leabman MK, Meng YG, Kelley RF, et al. Effects of altered FcgammaR binding on antibody pharmacokinetics in cynomolgus monkeys. mAbs. 2013;5(6):896–903.
   PubMed Web of Science ®Google Scholar
• Fjaertoft G, Hakansson L, Foucard T, et al. CD64 (Fcgamma receptor I) cell surface expression on maturing neutrophils from preterm and term newborn infants. Acta Paediatr. 2005;94(3):295–302.
   PubMed Web of Science ®Google Scholar
• Maeda M, Van Schie RC, Yuksel B, et al. Differential expression of Fc receptors for IgG by monocytes and granulocytes from neonates and adults. Clin Exp Immunol. 1996;103(2):343–347.
   PubMed Web of Science ®Google Scholar
• Smith JB, Campbell DE, Ludomirsky A, et al. Expression of the complement receptors CR1 and CR3 and the type III Fc gamma receptor on neutrophils from newborn infants and from fetuses with Rh disease. Pediatr Res. 1990;28(2):120–126.
   PubMed Web of Science ®Google Scholar
• Takahashi N, Nishida H, Kuratsuji T. Fc gamma RI and Fc gamma RIII on polymorphonuclear leucocytes in cord blood. Arch Dis Child Fetal Neonatal Ed. 1994;70(1):F31–F5.
   PubMedGoogle Scholar
• Nowak J, Szymczynski G. T and B lymphocytes in the ontogenetic development of man. Arch Immunol Ther Exp (Warsz). 1979;27(1–2):159–163.
   PubMed Web of Science ®Google Scholar
• Agostini C, Colombatti M, Sanzari M, et al. B lymphocytes in newborns. Arch Immunol Ther Exp (Warsz). 1981;29(1):79–84.
   PubMed Web of Science ®Google Scholar
• Jessup CF, Ridings J, Ho A, et al. The Fc receptor for IgG (Fc gamma RII; CD32) on human neonatal B lymphocytes. Hum Immunol. 2001;62(7):679–685.
   PubMed Web of Science ®Google Scholar
• Hallberg T, Hallberg A. Lymphocyte markers in newborn infants. Acta Pathol Microbiol Scand C. 1976;84c(6):477–484.
   PubMedGoogle Scholar
• Martins JP, Kennedy PJ, Santos HA, et al. A comprehensive review of the neonatal Fc receptor and its application in drug delivery. Pharmacol Ther. 2016;161:22–39.
   PubMed Web of Science ®Google Scholar
• McCarthy KM, Yoong Y, Simister NE. Bidirectional transcytosis of IgG by the rat neonatal Fc receptor expressed in a rat kidney cell line: a system to study protein transport across epithelia. J Cell Sci. 2000;113(Pt7):1277–1285.
   PubMedGoogle Scholar
• Kobayashi N, Suzuki Y, Tsuge T, et al. FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells. Am J Physiol Renal Physiol. 2002;282(2):F358–F65.
   PubMed Web of Science ®Google Scholar
• Ramalingam TS, Detmer SA, Martin WL, et al. IgG transcytosis and recycling by FcRn expressed in MDCK cells reveals ligand-induced redistribution. EMBO J. 2002;21(4):590–601.
   PubMed Web of Science ®Google Scholar
• Ghetie V, Hubbard JG, Kim J-K, et al. Abnormally short serum half-lives of IgG in β2-microglobulin-deficient mice. Eur J Immunol. 1996;26(3):690–696.
   PubMed Web of Science ®Google Scholar
• Israel EJ, Wilsker DF, Hayes KC, et al. Increased clearance of IgG in mice that lack β2-microglobulin: possible protective role of FcRn. Immunology. 1996;89(4):573–578.
   PubMed Web of Science ®Google Scholar
• Ko S-Y, Pegu A, Rudicell RS, et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature. 2014;514:642.
   PubMed Web of Science ®Google Scholar
• Zalevsky J, Chamberlain AK, Horton HM, et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol. 2010;28:157.
   PubMed Web of Science ®Google Scholar
• Ng CM, Fielder PJ, Jin J, et al. Mechanism-based competitive binding model to investigate the effect of neonatal Fc receptor binding affinity on the pharmacokinetics of humanized anti-VEGF monoclonal IgG1 antibody in cynomolgus monkey. AAPS J. 2016;18(4):948–959.
   PubMed Web of Science ®Google Scholar
• Yang D, Giragossian C, Castellano S, et al. Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn. mAbs. 2017;9(7):1105–1117.
   PubMed Web of Science ®Google Scholar
• Challa DK, Velmurugan R, Ober RJ, et al. FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions. Cur Top Microbiol Immunol. 2014;382:249–272.
   PubMed Web of Science ®Google Scholar
• Sand KMK, Bern M, Nilsen J, et al. Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics. Front Immunol. 2014;5:682.
   PubMed Web of Science ®Google Scholar
• Tian Z, Sutton BJ, Zhang X. Distribution of rat neonatal Fc receptor in the principal organs of neonatal and pubertal rats. J Recept Signal Transduct Res. 2014;34(2):137–142.
   PubMed Web of Science ®Google Scholar
• Cianga C, Cianga P, Plamadeala P, et al. Nonclassical major histocompatibility complex I-like Fc neonatal receptor (FcRn) expression in neonatal human tissues. Hum Immunol. 2011;72(12):1176–1187.
   PubMed Web of Science ®Google Scholar
• Borvak J, Richardson J, Medesan C, et al. Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice. Int Immunol. 1998;10(9):1289–1298.
   PubMed Web of Science ®Google Scholar
• Montoyo HP, Vaccaro C, Hafner M, et al. Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice. Proc Natl Acad Sci U S A. 2009;106(8):2788–2793.
   PubMed Web of Science ®Google Scholar
• Mankarious S, Lee M, Fischer S, et al. The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J Lab Clin Med. 1988;112(5):634–640.
   PubMed Web of Science ®Google Scholar
• Oxelius V-A. IgG subclass levels in infancy and childhood. Acta Paeiatr. 1979;68(1):23–27.
   PubMed Web of Science ®Google Scholar
• Schur PH, Rosen F, Norman ME. Immunoglobulin subclasses in normal children. Pediatr Res. 1979;13(3):181–183.
   PubMed Web of Science ®Google Scholar
• Aksu G, Genel F, Koturoglu G, et al. Serum immunoglobulin (IgG, IgM, IgA) and IgG subclass concentrations in healthy children: a study using nephelometric technique. Turk J Pediatr. 2006;48(1):19–24.
   PubMed Web of Science ®Google Scholar
• Wallace DK, Kraker RT, Freedman SF, et al. Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: A phase 1 dosing study. JAMA Ophthalmol. 2017;135(6):654–656.
   PubMed Web of Science ®Google Scholar
• Stahl A, Krohne TU, Eter N, et al. Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: A randomized clinical trial. JAMA Pediatr. 2018;172:278.
   PubMed Web of Science ®Google Scholar
• Zhao L, Ji P, Li Z, et al. The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model. J Clin Pharmacol. 2013;53(3):314–325.
   PubMed Web of Science ®Google Scholar
• Ortega H, Yancey S, Cozens S. Pharmacokinetics and absolute bioavailability of mepolizumab following administration at subcutaneous and intramuscular sites. Clin Pharmacol Drug Dev. 2014;3(1):57–62.
   PubMed Web of Science ®Google Scholar
• Richter WF, Jacobsen B. Subcutaneous absorption of biotherapeutics: knowns and unknowns. Drug Metab Dispos. 2014;42(11):1881–1889.
   PubMedGoogle Scholar
• Kota J, Machavaram KK, McLennan DN, et al. Lymphatic absorption of subcutaneously administered proteins: influence of different injection sites on the absorption of darbepoetin alfa using a sheep model. Drug Metab Dispos. 2007;35(12):2211–2217.
   PubMed Web of Science ®Google Scholar
• Wang EQ, Plotka A, Salageanu J, et al. Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK9, after single subcutaneous injection at three sites. Cardiovasc Ther. 2017;35:5.
   Web of Science ®Google Scholar
• Lunven C, Paehler T, Poitiers F, et al. A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects. Cardiovasc Ther. 2014;32(6):297–301.
   PubMed Web of Science ®Google Scholar
• Cai WW, Fiscella M, Chen C, et al. Bioavailability, pharmacokinetics, and safety of belimumab administered subcutaneously in healthy subjects. Clin Pharmacol Drug Dev. 2013;2(4):349–357.
   PubMed Web of Science ®Google Scholar
• Xu Z, Wang Q, Zhuang Y, et al. Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects. J Clin Pharmacol. 2010;50(3):276–284.
   PubMed Web of Science ®Google Scholar
• Dahlberg AM, Kaminskas LM, Smith A, et al. The lymphatic system plays a major role in the intravenous and subcutaneous pharmacokinetics of trastuzumab in rats. Mol Pharm. 2014;11(2):496–504.
   PubMedGoogle Scholar
• Kagan L, Gershkovich P, Mendelman A, et al. The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model. Eur J Pharm Biopharm. 2007;67(3):759–765.
   PubMed Web of Science ®Google Scholar
• Deng R, Meng YG, Hoyte K, et al. Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice. mAbs. 2012;4(1):101–109.
   PubMed Web of Science ®Google Scholar
• Ternant D, Paintaud G, Trachtman H, et al. A possible influence of age on absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS). Eur J Clin Pharmacol. 2016;72(2):253–255.
   PubMed Web of Science ®Google Scholar
• Ku LC, Smith PB. Dosing in neonates: special considerations in physiology and trial design. Pediatr Res. 2015;77:2–9.
   PubMed Web of Science ®Google Scholar
• Rakhmanina NY, Van Den Anker JN. Pharmacological research in pediatrics: from neonates to adolescents. Adv Drug Deliv Rev. 2006;58(1):4–14.
   PubMed Web of Science ®Google Scholar
• Bellini C, Boccardo F, Bonioli E, et al. Lymphodynamics in the fetus and newborn. Lymphology. 2006;39(3):110–117.
   PubMed Web of Science ®Google Scholar
• Sholler GF, Celermajer JM, Whight CM, et al. Echo doppler assessment of cardiac output and its relation to growth in normal infants. Am J Cardiol. 1987;60(13):1112–1116.
   PubMed Web of Science ®Google Scholar
• Johnson SA, Vander Straten MC, Parellada JA, et al. Thoracic duct function in fetal, newborn, and adult sheep. Lymphology. 1996;29(2):50–56.
   PubMed Web of Science ®Google Scholar
• Holman R. The flow and protein content of subcutaneous lymph in dogs of different ages. Am J Physiol. 1937;118(2):354–358.
   Google Scholar
• Boston RW, Humphreys PW, Reynolds EOR, et al. Lymph-flow and clearance of liquid from the lungs of the foetal lamb. Lancet. 1965;286(7410):473–474.
   Google Scholar
• Kong L, Bhatt AR, Demny AB, et al. Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2015;56(2):956–961.
   PubMed Web of Science ®Google Scholar
• Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2012;153(2):327–33.e1.
   PubMed Web of Science ®Google Scholar
• Wu WC, Shih CP, Lien R, et al. Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. Retina. 2017;37(4):694–701.
   PubMed Web of Science ®Google Scholar
• Hong YR, Kim YH, Kim SY, et al. Plasma concentrations of vascular endothelial growth factor in retinopathy of prematurity after intravitreal bevacizumab injection. Retina. 2015;35(9):1772–1777.
   PubMed Web of Science ®Google Scholar
• Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab and ranibizumab. Retina. 2017;37(10):1847–1858.
   PubMed Web of Science ®Google Scholar
• Kim H, Fariss RN, Zhang C, et al. Mapping of the neonatal Fc receptor in the rodent eye. Invest Ophthalmol Vis Sci. 2008;49(5):2025–2029.
   PubMed Web of Science ®Google Scholar
• Eigenmann MJ, Karlsen TV, Krippendorff B-F, et al. Interstitial IgG antibody pharmacokinetics assessed by combined in vivo- and physiologically-based pharmacokinetic modelling approaches. J Physiol. 2017;595(24):7311–7330.
   PubMed Web of Science ®Google Scholar
• Jadhav SB, Khaowroongrueng V, Fueth M, et al. Tissue distribution of a therapeutic monoclonal antibody determined by large pore microdialysis. J Pharm Sci. 2017;106(9):2853–2859.
   PubMed Web of Science ®Google Scholar
• Bjorkman S. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A. Haemophilia. 2010;16(4):597–605.
   PubMed Web of Science ®Google Scholar
• Bjorkman S, Blanchette VS, Fischer K, et al. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost. 2010;8(4):730–736.
   PubMed Web of Science ®Google Scholar
• Singh AP, Shah DK. Application of a PK-PD modeling and simulation-based strategy for clinical translation of antibody-drug conjugates: a case study with trastuzumab emtansine (T-DM1). AAPS J. 2017;19(4):1054–1070.
   PubMed Web of Science ®Google Scholar